Technology Innovation Institute’s Cryptography Research Centre in Abu Dhabi Collaborates with Yale University
6.1.2021 13:15:00 EET | Business Wire | Press release
Abu Dhabi and the UAE are working to pioneer breakthroughs in post-quantum cryptography and neuromorphic computing through an international partnership between Technology Innovation Institute’s (TII) Cryptography Research Centre (CRC) and Yale University, an Ivy League research university in Connecticut, United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005376/en/
Dr. Najwa Aaraj, Chief Researcher at Cryptography Research Centre (Photo: AETOSWire)
The two institutions will first join forces on ‘Post-Quantum Lightweight Crypto Hardware Accelerators and Trusted Execution Environment Designs’, a project at the intersection of emerging technologies that focuses on developing quantum-resistant crypto schemes within the context of emerging quantum algorithms that can be run on a sufficiently large quantum computer. By leveraging post-quantum cryptographic (PQC) algorithms, the project aims to guarantee the necessary measures of security even as today’s public cryptographic standards, such as RSA and Elliptic Curve Cryptography (ECC), become ineffective when a powerful quantum computer is built and can run Shor’s quantum algorithm. The project is also exploring post-quantum lightweight cryptography with a focus on highly constrained devices.
The neuromorphic computing project, ‘Energy-based Probing for Robust and Explainable Spiking Neural Networks’, takes inspiration from the brain to create energy-efficient hardware for information processing and is capable of highly sophisticated tasks. The project examines Spiking Neural Networks (SNNs), which have become popular as an energy-efficient alternative for implementing standard artificial intelligence tasks. Spikes or binary events drive communication and computation in SNNs that are close to biological neuronal processing and offer the benefit of event-driven hardware operations.
The central focus of the collaboration is to explore the design space of the energy-accuracy-robustness-explainability trade-off and to design the hardware/software necessary to create truly functional intelligent systems. To ensure there is no overlap, both entities have been tasked with managing specific areas of the research in both projects.
Speaking on the partnership, Dr Najwa Aaraj, Chief Researcher at Cryptography Research Centre, said: “We are excited to work with peers from Yale University in carrying out groundbreaking research in these two vital fields. At the Cryptography Research Centre, we are creating a knowledge-driven ecosystem powered by like-minded scientists and researchers – all focused on designing breakthrough solutions in different areas of cryptography.”
Jakub Szefer, Associate Professor of Electrical Engineering and Computer Science, and Priya Panda, Assistant Professor of Electrical Engineering, from Yale University, said: “By working collaboratively with Cryptography Research Centre, we have an opportunity to apply shared expertise across post-quantum cryptography and neuromorphic computing research. We are optimistic that this partnership will yield effective research outcomes for greater impact.”
Technology Innovation Institute, the ‘applied research’ pillar of Advanced Technology Research Council (ATRC), is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge- based economy.
For more information about Cryptography Research Centre (CRC) please visit
tii.ae/cryptographytii.ae/cryptography
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005376/en/
Contact information
Technology Innovation Institute
Aisha Shaikh, +971555423718
aisha.shaikh@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
